Stockreport

Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET [Seeking Alpha]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF PRAX's Ulixacaltamide achieved primary endpoints in two phase 3 studies, positioning it as the first potential FDA-approved therapy for Essential Tremor, targeting a la [Read more]